BETA
Spinal implant developer and manufacturer with porous PEEK technology and a broader fusion and fixation portfolio.
Curiteva is a privately held spinal implant and manufacturing company founded in 2017. It describes itself as Huntsville-area based, while its current corporate headquarters address is in Tanner, Alabama. Its portfolio spans interbody implants, fixation systems, surgical instruments and biologic graft products.
The Inspire platform combines 3D-printed porous PEEK structures with surface technology. FDA records identify several interbody and laminoplasty systems, including a January 2026 decision spanning multiple porous PEEK families. Separate product families and multiple procedures should not be treated as one universally cleared system.
Company announcements describe more than 10,000 treated levels in January 2026 and plans for increased manufacturing capacity and an innovation center. Those are manufacturer-reported adoption and expansion signals, not audited outcomes or evidence that a planned facility is already operational. The company’s leadership page identifies Eric Linder as founder and CTO.
Curiteva’s Inspire/porous PEEK family has several 510(k) decisions, including standalone ALIF K250845 and cervical interbody K254061, which were absent from the earlier snapshot. Other fixation and navigation decisions are recorded separately. The company’s nanotechnology language does not constitute a separate FDA marketing pathway. [22][20][1][4][8][10][23][24]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [26][27]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Selected porous PEEK cervical, lumbar, laminoplasty and standalone ALIF systems; exact indication and model mapping is device-specific. [20][1][2][3][4]
FDA-clearedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Commercial expansion includes Inspire product-line growth, manufacturing capacity and training infrastructure. Selected porous PEEK decisions do not exhaust the wider fixation, instrumentation or biologic portfolio. [23]
Company announced cumulative treated levels, not a unique patient count or comparative outcome. [23]
FDA recorded K252205 across several porous PEEK system families. [1]
Company described increased Inspire manufacturing capacity and a planned surgical training, teaching and prototyping center. Completion is not assumed. [23]
Accessed 10/29/2026